Novo Nordisk (ADR) (NVO)
Develops GLP-1 and insulin medicines for diabetes, obesity and rare diseases.
$39.78
vs last close−0.02 (−0.06%)
In millions of USD, except per-share figures · converted from DKK at the latest rate
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8,996 | 10,089 | 10,010 | 10,425 | 10,923 | 13,125 | 11,961 | 11,773 | 11,485 | 12,123 | 14,831 | 12,023 |
| Cost of revenue | 1,488 | 1,534 | 1,519 | 1,574 | 1,732 | 1,995 | 1,974 | 1,968 | 2,742 | 2,320 | 2,083 | 2,619 |
| Gross profit | 7,508 | 8,555 | 8,491 | 8,852 | 9,191 | 11,130 | 9,987 | 9,805 | 8,742 | 9,803 | 12,748 | 9,403 |
| 3,386 | 4,455 | 3,613 | 4,879 | 4,010 | 5,502 | 4,045 | 4,681 | 5,115 | 4,942 | 3,616 | 5,258 | |
| Research & development | 1,245 | 1,602 | 1,318 | 2,476 | 1,453 | 2,114 | 1,579 | 1,791 | 2,358 | 2,244 | 1,575 | 2,725 |
| 2,156 | 2,853 | 2,208 | 2,465 | 2,542 | 3,107 | 2,468 | 2,887 | 2,739 | 2,671 | 2,025 | 2,498 | |
| Selling & marketing | 1,964 | 2,630 | 2,031 | 2,288 | 2,330 | 2,865 | 2,281 | 2,686 | 2,450 | 2,434 | 1,850 | 2,297 |
| General & administrative | 192 | 223 | 177 | 177 | 212 | 242 | 187 | 202 | 289 | 237 | 175 | 201 |
| Other expenses | −15 | 0 | 87 | −62 | 15 | 282 | −2 | 4 | 18 | 27 | 16 | 36 |
| Operating income | 4,122 | 4,100 | 4,878 | 3,973 | 5,181 | 5,627 | 5,942 | 5,124 | 3,628 | 4,861 | 9,132 | 4,145 |
| 176 | 131 | 11 | −92 | 86 | −181 | −269 | 55 | 281 | 375 | 391 | −28 | |
| Interest income | 508 | 0 | 329 | 147 | 212 | 599 | 525 | 814 | 281 | 375 | 927 | 201 |
| Interest expense | 332 | 140 | 318 | 239 | 126 | 780 | 794 | 759 | 0 | 0 | 536 | 230 |
| Other non-operating income | −508 | 191 | −329 | −147 | −212 | −599 | −525 | −814 | −281 | −375 | −927 | −201 |
| Income before tax | 4,299 | 4,231 | 4,889 | 3,880 | 5,267 | 5,447 | 5,673 | 5,178 | 3,909 | 5,236 | 9,523 | 4,117 |
| Income tax expense | 855 | 867 | 997 | 809 | 1,085 | 1,122 | 1,225 | 1,119 | 844 | 1,117 | 2,086 | 902 |
| Net income from continuing operations | 3,443 | 3,364 | 3,892 | 3,071 | 4,182 | 4,324 | 4,447 | 4,060 | 3,064 | 4,119 | 7,438 | 3,215 |
| Net income | 3,443 | 3,364 | 3,892 | 3,071 | 4,182 | 4,324 | 4,447 | 4,060 | 3,064 | 4,119 | 7,438 | 3,215 |
| EPS, basic | $0.77 | $0.75 | $0.87 | $0.69 | $0.94 | $0.97 | $1.00 | $0.91 | $0.69 | $0.93 | $1.67 | $0.73 |
| EPS, diluted | $0.77 | $0.75 | $0.87 | $0.69 | $0.94 | $0.97 | $1.00 | $0.91 | $0.69 | $0.93 | $1.67 | $0.73 |
| Weighted average shares, basic | 4,477 | 4,465 | 4,460 | 4,458 | 4,454 | 4,454 | 4,440 | 4,447 | 4,446 | 4,448 | 4,443 | 4,428 |
| Weighted average shares, diluted | 4,489 | 4,477 | 4,471 | 4,465 | 4,461 | 4,461 | 4,446 | 4,447 | 4,447 | 4,448 | 4,449 | 4,436 |
| EBITDA | 5,017 | 4,367 | 5,653 | 5,474 | 5,722 | 7,023 | 7,053 | 6,678 | 5,097 | 6,088 | 10,601 | 5,925 |
| Depreciation & amortization | 387 | 458 | 446 | 1,355 | 329 | 796 | 587 | 740 | 1,188 | 852 | 542 | 1,578 |
| EBIT | 4,631 | 3,909 | 5,207 | 4,120 | 5,393 | 6,227 | 6,467 | 5,938 | 3,909 | 5,236 | 10,059 | 4,346 |